

Martin Thurnher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2366068/martin-thurnher-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

3,937
citations

34
h-index

61
g-index

94
ext. papers

4,254
ext. citations

5.5
avg, IF

5.05
L-index

#	Paper	IF	Citations
89	Control of Macrophage Inflammation by P2Y Purinergic Receptors. <i>Cells</i> , 2021 , 10,	7.9	9
88	Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
87	The human G protein-coupled ATP receptor P2Y is a target for anti-inflammatory strategies. <i>British Journal of Pharmacology</i> , 2021 , 178, 1541-1555	8.6	4
86	CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma. <i>BJU International</i> , 2021 , 128, 29-32	5.6	2
85	Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2805-2817	7.4	4
84	Lynch Syndrome: Its Impact on Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
83	Rare, but Severe: Vasculitis and Checkpoint Inhibitors. <i>European Urology Focus</i> , 2020 , 6, 609-612	5.1	5
82	Functional Phenotypes of Human $\gamma\delta$ T Cells in Lymphoid Stress Surveillance. <i>Cells</i> , 2020 , 9,	7.9	3
81	The Human G Protein-Coupled ATP Receptor P2Y Is Associated With IL-10 Driven Macrophage Differentiation. <i>Frontiers in Immunology</i> , 2019 , 10, 1870	8.4	8
80	Mevalonate Metabolism in Cancer Stemness and Trained Immunity. <i>Frontiers in Oncology</i> , 2018 , 8, 394	5.3	21
79	Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 427-440	7.4	36
78	Mevalonate metabolism governs cancer immune surveillance. <i>Oncotarget</i> , 2017 , 6, e1342917	7.2	19
77	Mevalonate Metabolism in Immuno-Oncology. <i>Frontiers in Immunology</i> , 2017 , 8, 1714	8.4	31
76	Small Drops Get Fat: Unexpected Fatty Acid in Cytoplasmic Lipid Droplets. <i>Cell Chemical Biology</i> , 2016 , 23, 637-8	8.2	1
75	Ecto-ATPase CD39 Inactivates Isoprenoid-Derived $\gamma\delta$ T Cell Phosphoantigens. <i>Cell Reports</i> , 2016 , 16, 444-456	10.6	24
74	Mevalonate metabolism in cancer. <i>Cancer Letters</i> , 2015 , 356, 192-6	9.9	38
73	T lymphocyte regulation by mevalonate metabolism. <i>Science Signaling</i> , 2015 , 8, re4	8.8	54

72	Stress-related and homeostatic cytokines regulate V β V δ T-cell surveillance of mevalonate metabolism. <i>OncImmunology</i> , 2014 , 3, e953410	7.2	29
71	Essential requirements of zoledronate-induced cytokine and T cell proliferative responses. <i>Journal of Immunology</i> , 2013 , 191, 1346-55	5.3	37
70	Regulation of mevalonate metabolism in cancer and immune cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013 , 1831, 1009-15	5	63
69	Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1407-13	7.4	18
68	Novel aspects of mevalonate pathway inhibitors as antitumor agents. <i>Clinical Cancer Research</i> , 2012 , 18, 3524-31	12.9	160
67	C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. <i>BJU International</i> , 2011 , 107, 1893-8	5.6	17
66	DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by T lymphocytes. <i>Blood</i> , 2011 , 118, 2743-51	2.2	60
65	Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. <i>Immunology and Cell Biology</i> , 2010 , 88, 424-30	5	89
64	IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. <i>Cancer Research</i> , 2010 , 70, 9611-20	10.1	47
63	Serum IgG against <i>Candida</i> predict survival in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1141-7	7.4	1
62	Dendritic Cell Vaccines 2010 , 267-276		
61	CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. <i>Blood</i> , 2009 , 114, 4422-31	2.2	36
60	Serum antibodies against <i>Saccharomyces cerevisiae</i> : a new prognostic indicator in metastatic renal-cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1207-14	7.4	1
59	Bee venom secretory phospholipase A2 and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 627-40	7.4	30
58	Antigen-independent immune responses after dendritic cell vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 897-903	7.4	14
57	Lipids in dendritic cell biology: messengers, effectors, and antigens. <i>Journal of Leukocyte Biology</i> , 2007 , 81, 154-60	6.5	14
56	Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 845-51	2.2	37
55	IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 1228-37	7.4	33

54	Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-biphosphate. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 1374-83	7.4	47
53	Generation of clinical-grade monocyte-derived dendritic cells using the CliniMACS system. <i>Methods in Molecular Medicine</i> , 2005 , 109, 71-82		5
52	Dendritic-cell activation by secretory phospholipase A2. <i>Blood</i> , 2005 , 105, 3583-7	2.2	23
51	The cyclopentenone prostaglandin PGA2 costimulates the maturation of human dendritic cells. <i>Experimental Hematology</i> , 2005 , 33, 144-50	3.1	7
50	Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 663-70	7.4	114
49	Ability of PSA-positive circulating macrophages to detect prostate cancer. <i>Prostate</i> , 2005 , 62, 290-8	4.2	8
48	Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 2459-65	12.9	76
47	Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. <i>Anticancer Research</i> , 2005 , 25, 2345-55	2.3	12
46	Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis. <i>Journal of Clinical Immunology</i> , 2004 , 24, 653-63	5.7	12
45	Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. <i>Microbes and Infection</i> , 2002 , 4, 945-53	9.3	124
44	Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations. <i>Blood</i> , 2002 , 99, 4053-62	2.2	26
43	An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. <i>Urology</i> , 2002 , 60, 521-6	1.6	28
42	Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production. <i>FEBS Letters</i> , 2002 , 511, 123-6	3.8	27
41	Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. <i>Clinical Cancer Research</i> , 2002 , 8, 3369-76	12.9	153
40	A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells. <i>Immunology Letters</i> , 2001 , 76, 63-7	4.1	22
39	The disabled dendritic cell. <i>FASEB Journal</i> , 2001 , 15, 1054-61	0.9	42
38	Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. <i>Journal of Immunology</i> , 2001 , 166, 7477-85	5.3	350
37	EXPRESSION AND IMMUNOGENICITY OF ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR IN HUMAN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001 , 165, 1705-1709	2.5	16

36	The disabled dendritic cell. <i>FASEB Journal</i> , 2001 , 15, 1054-1061	0.9	5
35	Effects of alpha1-adrenoceptor antagonists on cultured prostatic smooth muscle cells. <i>Prostate</i> , 2000 , 9, 34-41	4.2	12
34	Inhibition of Lncap prostate cancer cells by means of androgen receptor antisense oligonucleotides. <i>Cancer Gene Therapy</i> , 2000 , 7, 997-1007	5.4	138
33	Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. <i>Urologia Internationalis</i> , 1999 , 63, 151-9	1.9	56
32	CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS. <i>Journal of Urology</i> , 1999 , 161, 777-782	2.5	202
31	CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS. <i>Journal of Urology</i> , 1999 , 777-782	2.5	13
30	Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. <i>British Journal of Cancer</i> , 1998 , 78, 1004-11	8.7	35
29	Human monocyte-derived dendritic cells produce macrophage colony-stimulating factor: enhancement of c-fms expression by interleukin-10. <i>European Journal of Immunology</i> , 1998 , 28, 2283-8	6.1	31
28	Videomaging of prostatic stromal-cell contraction: an in vitro model for studying drug effects. <i>Prostate</i> , 1998 , 37, 209-14	4.2	22
27	Activation of human dendritic cells by bacillus Calmette-Guerin. <i>Journal of Urology</i> , 1998 , 159, 1488-92	2.5	26
26	Nordihydroguaiaretic acid blocks secretory and endocytic pathways in human dendritic cells. <i>Journal of Leukocyte Biology</i> , 1998 , 64, 747-52	6.5	16
25	Differential Deactivation of Human Dendritic Cells by Endotoxin Desensitization: Role of Tumor Necrosis Factor- α and Prostaglandin E2. <i>Blood</i> , 1998 , 91, 3112-3117	2.2	61
24	Dendritic cell-based immunotherapy of renal cell carcinoma. <i>Urologia Internationalis</i> , 1998 , 61, 67-71	1.9	34
23	Differential Deactivation of Human Dendritic Cells by Endotoxin Desensitization: Role of Tumor Necrosis Factor- α and Prostaglandin E2. <i>Blood</i> , 1998 , 91, 3112-3117	2.2	5
22	Videomaging of prostatic stromal-cell contraction: An in vitro model for studying drug effects 1998 , 37, 209		1
21	Human monocyte-derived dendritic cells produce macrophage colony-stimulating factor: enhancement of c-fms expression by interleukin-10 1998 , 28, 2283		1
20	The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guérin. Heterogeneity, structure, and role in the regulation of cytokine secretion. <i>Journal of Biological Chemistry</i> , 1997 , 272, 23094-103	5.4	107
19	Dendritic cells for the immunotherapy of renal cell carcinoma. <i>Urologia Internationalis</i> , 1997 , 59, 1-5	1.9	6

18	Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1603-8	16.6	238
17	A reliable system for the culture of human prostatic cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1997 , 33, 742-4	2.6	17
16	Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. <i>Prostate</i> , 1997 , 30, 117-29	4.2	66
15	Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. <i>Prostate</i> , 1997 , 31, 223-33	4.2	74
14	Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. <i>International Journal of Cancer</i> , 1997 , 70, 128-34	7.5	93
13	Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate 1997 , 31, 223		2
12	Human renal-cell carcinoma tissue contains dendritic cells. <i>International Journal of Cancer</i> , 1996 , 68, 1-7	7.5	121
11	Regulation of prostatic growth and function by peptide growth factors. <i>Prostate</i> , 1996 , 28, 392-405	4.2	223
10	Human renal-cell carcinoma tissue contains dendritic cells 1996 , 68, 1		1
9	Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. <i>International Journal of Cancer</i> , 1995 , 62, 559-64	7.5	16
8	Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. <i>International Journal of Cancer</i> , 1995 , 63, 627-32	7.5	41
7	Carbohydrate receptor-mediated gene transfer to human T leukaemic cells. <i>Glycobiology</i> , 1994 , 4, 429-35	3.8	40
6	The cell-specific expression of glycan antigens exemplified by the deficiency of beta 1,3 galactosyltransferase in the Tn-syndrome. <i>Transfusion Clinique Et Biologique</i> , 1994 , 1, 103-8	1.9	4
5	Mucin Type Galactosyltransferase: Enzymology and Deficiency in the Tn-Syndrome.. <i>Trends in Glycoscience and Glycotechnology</i> , 1994 , 6, 51-63	0.1	4
4	Use of O-glycosylation-defective human lymphoid cell lines and flow cytometry to delineate the specificity of Moluccella laevis lectin and monoclonal antibody 5F4 for the Tn antigen (GalNAc alpha 1-O-Ser/Thr). <i>Immunology Letters</i> , 1993 , 36, 239-43	4.1	26
3	Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. <i>Journal of Clinical Investigation</i> , 1993 , 91, 2103-10	15.9	56
2	T cell clones with normal or defective O-galactosylation from a patient with permanent mixed-field polyagglutinability. <i>European Journal of Immunology</i> , 1992 , 22, 1835-42	6.1	28
1	Galactosyltransferase and sialyltransferase are located in different subcellular compartments in HeLa cells. <i>Experimental Cell Research</i> , 1987 , 173, 267-73	4.2	45

